Lannett (LCI) to Release Quarterly Earnings on Tuesday

Lannett (NYSE:LCI) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, January 30th.

Lannett (NYSE:LCI) last released its quarterly earnings results on Monday, November 6th. The company reported $0.60 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.08. Lannett had a return on equity of 18.23% and a net margin of 6.67%. The firm had revenue of $155.00 million for the quarter, compared to analyst estimates of $153.62 million. During the same quarter last year, the company posted $0.77 earnings per share. The business’s revenue was down 4.1% on a year-over-year basis. On average, analysts expect Lannett to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Lannett (NYSE:LCI) opened at $23.05 on Tuesday. The company has a current ratio of 2.52, a quick ratio of 1.90 and a debt-to-equity ratio of 1.44. Lannett has a twelve month low of $14.90 and a twelve month high of $30.35. The stock has a market capitalization of $867.09, a PE ratio of 8.55, a P/E/G ratio of 1.49 and a beta of 2.85.

In other Lannett news, major shareholder David Farber sold 10,000 shares of Lannett stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $25.03, for a total value of $250,300.00. Following the sale, the insider now owns 4,211,069 shares of the company’s stock, valued at approximately $105,403,057.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Arthur P. Bedrosian sold 7,422 shares of Lannett stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $25.20, for a total value of $187,034.40. Following the completion of the sale, the chief executive officer now directly owns 679,001 shares in the company, valued at approximately $17,110,825.20. The disclosure for this sale can be found here. Insiders sold a total of 140,000 shares of company stock worth $3,681,091 in the last ninety days. 14.72% of the stock is owned by corporate insiders.

A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered Lannett from a “buy” rating to a “hold” rating in a report on Wednesday, December 13th. Oppenheimer reissued a “hold” rating on shares of Lannett in a report on Monday, December 11th. ValuEngine raised Lannett from a “hold” rating to a “buy” rating in a report on Saturday, November 25th. Finally, BMO Capital Markets lifted their price objective on Lannett from $20.00 to $22.00 and gave the company a “market perform” rating in a report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $23.60.

COPYRIGHT VIOLATION NOTICE: “Lannett (LCI) to Release Quarterly Earnings on Tuesday” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/23/lannett-lci-to-release-quarterly-earnings-on-tuesday.html.

Lannett Company Profile

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Earnings History for Lannett (NYSE:LCI)

Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply